{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:59:47Z","timestamp":1785196787993,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.japh.2026.103117","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:42:49Z","timestamp":1776814969000},"page":"103117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3177-5036","authenticated-orcid":false,"given":"Saba","family":"Hajibandeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-An","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1441-1814","authenticated-orcid":false,"given":"Hsuan-Hui \u201cGrace\u201d","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-3669","authenticated-orcid":false,"given":"Yi-Fen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Hsun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8853-0115","authenticated-orcid":false,"given":"Shin-Yuh","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-4363","authenticated-orcid":false,"given":"Chi-Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2026.103117_bib2","author":"Fryar"},{"issue":"25","key":"10.1016\/j.japh.2026.103117_bib5","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.japh.2026.103117_bib6","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00228-024-03755-w","article-title":"The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review","volume":"80","author":"Asiabar","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.japh.2026.103117_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2025","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.japh.2026.103117_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.japh.2026.103117_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/obr.12839","article-title":"Semaglutide as a promising antiobesity drug","volume":"20","author":"Christou","year":"2019","journal-title":"Obes Rev"},{"issue":"12","key":"10.1016\/j.japh.2026.103117_bib13","article-title":"Comparative efficacy of semaglutide versus liraglutide or efinopegdutide on weight loss in obese patients: a systematic review and meta-analysis","volume":"16","author":"Wen","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.japh.2026.103117_bib14","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"10403","key":"10.1016\/j.japh.2026.103117_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.japh.2026.103117_bib16","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1007\/s11695-022-06211-9","article-title":"The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis","volume":"32","author":"Lautenbach","year":"2022","journal-title":"Obes Surg"},{"issue":"5","key":"10.1016\/j.japh.2026.103117_bib17","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11695-024-07175-8","article-title":"Glucagon-like peptide-1 receptor agonists in post-bariatric surgery patients: a systematic review and meta-analysis","volume":"34","author":"Dutta","year":"2024","journal-title":"Obes Surg"},{"issue":"3","key":"10.1016\/j.japh.2026.103117_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.japh.2026.103117_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis","volume":"37","author":"Tan","year":"2022","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"14","key":"10.1016\/j.japh.2026.103117_bib20","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.japh.2026.103117_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.japh.2026.103117_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"11","key":"10.1016\/j.japh.2026.103117_bib25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.japh.2026.103117_bib26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.japh.2026.103117_bib27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.japh.2026.103117_bib28","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-Weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.japh.2026.103117_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2026.103117_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.japh.2026.103117_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/ph17020147","article-title":"Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the European Pharmacovigilance database","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.japh.2026.103117_bib34","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.japh.2026.103117_bib36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","article-title":"Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"issue":"7","key":"10.1016\/j.japh.2026.103117_bib37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12630-024-02719-z","article-title":"Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study","volume":"71","author":"Wu","year":"2024","journal-title":"Can J Anaesth"},{"issue":"8","key":"10.1016\/j.japh.2026.103117_bib38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can J Anaesth"},{"issue":"7","key":"10.1016\/j.japh.2026.103117_bib39","article-title":"Anesthesia considerations for a patient on semaglutide and delayed gastric emptying","volume":"15","author":"Fujino","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib40","article-title":"Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss","volume":"12","author":"Avraham","year":"2024","journal-title":"Anaesth Rep"},{"issue":"12","key":"10.1016\/j.japh.2026.103117_bib41","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"23","author":"Kindel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.japh.2026.103117_bib42","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"issue":"5","key":"10.1016\/j.japh.2026.103117_bib43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0310057X251355288","article-title":"2025 ADS\/ANZCA\/GESA\/NACOS clinical practice recommendations on the peri-procedural use of GLP-1\/GIP receptor agonists","volume":"53","author":"Hocking","year":"2025","journal-title":"Anaesth Intensive Care"},{"issue":"suppl 1","key":"10.1016\/j.japh.2026.103117_bib44","first-page":"S339","article-title":"16. Diabetes care in the hospital: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.japh.2026.103117_bib45","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jama.2025.14392","article-title":"New molecules and indications for GLP-1 medicines","volume":"334","author":"Gonzalez-Rellan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.japh.2026.103117_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial","volume":"32","author":"Edison","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.japh.2026.103117_bib49","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.japh.2026.103117_bib50","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1111\/bcp.14913","article-title":"Oral drug dosing following bariatric surgery: general concepts and specific dosing advice","volume":"87","author":"Kingma","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.japh.2026.103117_bib51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.2025.20301","article-title":"Combining medications with bariatric surgery to treat obesity","volume":"335","author":"Morton","year":"2026","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.japh.2026.103117_bib52","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.japh.2026.103117_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13350","article-title":"Prevalence of and factors associated with primary medication non-adherence in chronic disease: a systematic review and meta-analysis","volume":"73","author":"Cheen","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.japh.2026.103117_bib54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/fampra\/cmac110","article-title":"Evaluation of a pharmacist's impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting","volume":"40","author":"Crocetta","year":"2023","journal-title":"Fam Pract"},{"issue":"4","key":"10.1016\/j.japh.2026.103117_bib55","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.japh.2023.03.011","article-title":"Impact of a pharmacist-led, primary medication nonadherence intervention program on prescription fills in underserved patient populations","volume":"63","author":"Cason","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"6","key":"10.1016\/j.japh.2026.103117_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2025.102490","article-title":"Implementing a community health worker model to address health-related social needs in a community pharmacy network: a pragmatic evaluation","volume":"65","author":"Daly","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2","key":"10.1016\/j.japh.2026.103117_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2025.103016","article-title":"Pharmacist's role in addressing barriers to continuous glucose monitoring within underserved communities","volume":"66","author":"Cellino","year":"2026","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"20","key":"10.1016\/j.japh.2026.103117_bib58","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.japh.2026.103117_bib59","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease - 2025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.japh.2026.103117_bib60","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:31:19Z","timestamp":1785195079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1544319126001020"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103117","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103117"}}